drugset / Trial / NCT02325518

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

NCT02325518

Phase 4 Completed 218 enrolled Alcon, a Novartis Company
RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.

Timeline

Start
2014-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brinzolamide Small molecule 1 % Other
Comparator Dorzolamide Small molecule 1 % Other
Background Timolol Other / unclassified 0.5 % Other